While several FDA-approved antibodies, such as nivolumab and pembrolizumab, have shown success in blocking these pathways, tumors often develop resistance due to mechanisms like PD-L1 downregulation and low CD8+ T cell frequency in the tumor microenvironment (TME) [117]. This evidence concerns the gene CD8A and neoplasm.